Sawgrass Asset Management LLC Trims Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Sawgrass Asset Management LLC cut its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 7.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,891 shares of the biotechnology company’s stock after selling 1,377 shares during the quarter. Sawgrass Asset Management LLC’s holdings in ADMA Biologics were worth $189,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. EntryPoint Capital LLC acquired a new stake in ADMA Biologics in the first quarter valued at approximately $31,000. Simplicity Wealth LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at $68,000. AJOVista LLC purchased a new stake in ADMA Biologics in the 4th quarter worth $77,000. Oxford Asset Management LLP acquired a new position in ADMA Biologics during the fourth quarter worth $83,000. Finally, CWM LLC raised its position in ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 4,367 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Mizuho boosted their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. HC Wainwright increased their target price on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. Raymond James raised their target price on ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a research report on Friday, May 10th. Finally, Cantor Fitzgerald boosted their price target on ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and a consensus price target of $15.50.

Insider Activity

In related news, CEO Adam S. Grossman sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at $22,313,412. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Price Performance

ADMA stock traded down $0.04 during mid-day trading on Friday, reaching $17.55. The company’s stock had a trading volume of 2,765,379 shares, compared to its average volume of 3,046,072. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The company’s 50 day moving average is $12.46 and its two-hundred day moving average is $8.76. ADMA Biologics, Inc. has a fifty-two week low of $3.06 and a fifty-two week high of $17.87. The stock has a market cap of $4.07 billion, a PE ratio of -877.50 and a beta of 0.55.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The business’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.02) earnings per share. Equities research analysts expect that ADMA Biologics, Inc. will post 0.35 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.